Pazopanib has equivalent anti-tumor effectiveness and lower Total costs than Sunitinib for treating metastatic or advanced renal cell carcinoma: a meta-analysis-Reference-Cited by-同舟云学术

Pazopanib has equivalent anti-tumor effectiveness and lower Total costs than Sunitinib for treating metastatic or advanced renal cell carcinoma: a meta-analysis

Published:2019-05-23 Issue:1 Volume:19 Page:
ISSN:1471-2407
Container-title:BMC Cancer
language:en
Short-container-title:BMC Cancer

Author:

Deng Huan,Huang Yu,Hong Zhengdong,Yuan Xuhui,Cao Zhi,Wei Yiping,Zhang Wenxiong^ORCID

Funder

National Natural Science Foundation of China

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Genetics,Oncology

Link

http://link.springer.com/content/pdf/10.1186/s12885-019-5704-3.pdf

Reference36 articles.

1. Siegel RL, Miller KD, Jemal A, et al. Cancer statistics, 2018. CA Cancer J Clin. 2018;68(1):7–30.

2. Janzen NK, Kim HL, Figlin RA, et al. Surveillance after radical or partial nephrectomy for localized renal cell carcinoma and management of recurrent disease. Urol Clin North Am. 2003;30:843–52.

3. Escudier B, Eisen T, Porta C, et al. Renal cell carcinoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2012;23(Suppl 7):vii65–71.

4. Motzer RJ, Agarwal N, Beard C, et al. NCCN clinical practice guidelines in oncology: kidney cancer. J Natl Compr Cancer Netw. 2009;7:618–30.

5. Gore ME, Szczylik C, Porta C, et al. Safety and efficacy of Sunitinib for metastatic renal-cell carcinoma: an expanded-access trial. Lancet Oncol. 2009;10(8):757–63.

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Immunomodulatory effects of antiangiogenic tyrosine kinase inhibitors in renal cell carcinoma models: Impact on following anti-PD-1 treatments;Biochemical Pharmacology;2024-08

2. Metabolomics Reveals Tyrosine Kinase Inhibitor Resistance-Associated Metabolic Events in Human Metastatic Renal Cancer Cells;International Journal of Molecular Sciences;2024-06-07

3. ExPert ConsEnsus on the management of Advanced clear-cell RenaL celL carcinoma: INDIAn Perspective (PEARL-INDIA);BMC Cancer;2023-08-09

4. Optimal sequencing of the first- and second-line target therapies in metastatic renal cell carcinoma: based on nationally representative data analysis from the Korean National Health Insurance System;BMC Cancer;2023-05-30

5. Experimental FT-IR and UV–Vis spectroscopic studies and molecular docking analysis of anti-cancer drugs Exemestane and Pazopanib;Journal of Molecular Structure;2022-09